Evidence map›Paper›PMID 38196192›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2024

Targeting SRSF3 restores immune mRNA translation in microglia/macrophages following cerebral ischemia.

Reza Rahimian, Revathy Guruswamy, Hejer Boutej, Pierre Cordeau, Yuan Cheng Weng, Jasna Kriz

Open access · hybridAbstract read
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Dysregulation of SRSF3/International journal of biological sciences · 2025
    Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Reza RahimianCERVO Brain Research Centre and Department of Psychiatry and Neuroscience, Université Laval, Québec, QC G1J 2G3, Canada.
Revathy GuruswamyCERVO Brain Research Centre and Department of Psychiatry and Neuroscience, Université Laval, Québec, QC G1J 2G3, Canada.
Hejer BoutejCERVO Brain Research Centre and Department of Psychiatry and Neuroscience, Université Laval, Québec, QC G1J 2G3, Canada.
Pierre CordeauCERVO Brain Research Centre and Department of Psychiatry and Neuroscience, Université Laval, Québec, QC G1J 2G3, Canada.
Yuan Cheng WengCERVO Brain Research Centre and Department of Psychiatry and Neuroscience, Université Laval, Québec, QC G1J 2G3, Canada.
Jasna KrizCERVO Brain Research Centre and Department of Psychiatry and Neuroscience, Université Laval, Québec, QC G1J 2G3, Canada; Faculty of Medicine, Université Laval, Québec, QC G1J 2G3, Canada. Electronic address: jasna.kriz@fmed.ulaval.ca.
Université Laval · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We recently described a novel ribosome-based regulatory mechanism/checkpoint that controls innate immune gene translation and microglial activation in non-sterile inflammation orchestrated by RNA binding protein SRSF3. Here we describe a role of SRSF3 in the regulation of microglia/macrophage activation phenotypes after experimental stroke. Using a model-system for analysis of the dynamic translational state of microglial ribosomes we show that 24 h after stroke highly upregulated immune mRNAs are not translated resulting in a marked dissociation of mRNA and protein networks in activated microglia/macrophages. Next, microglial activation after stroke was characterized by a robust increase in pSRSF3/SRSF3 expression levels. Targeted knockdown of SRSF3 using intranasal delivery of siRNA 24 h after stroke caused a marked knockdown of endogenous protein. Further analyses revealed that treatment with SRSF3-siRNA alleviated translational arrest of selected genes and induced a transient but significant increase in innate immune signaling and IBA1+ immunoreactivity peaking 5 days after initial injury. Importantly, delayed SRSF3-mediated increase in immune signaling markedly reduced the size of ischemic lesion measured 7 days after stroke. Together, our findings suggest that targeting SRSF3 and immune mRNA translation may open new avenues for molecular/therapeutic reprogramming of innate immune response after ischemic injury.

Indexed as

Brain IschemiaStrokeHumansMacrophagesMicrogliaProtein BiosynthesisRNA, MessengerRNA, Small InterferingSerine-Arginine Splicing FactorsRNA, MessengerRNA, Small InterferingSerine-Arginine Splicing FactorsSRSF3 protein, humanimmune responseischemic strokemicrogliaproteomicribosomal check-pointSRSF3transcriptomic

Identifiers

PMID38196192
PMCPMC10928149
OpenAlexW4390674800

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.